SCHEMBL20265298

SCHEMBL20265298

NNc1ncc(Br)c2cccnc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ MAPT P10636 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ APAF1 O14727 1/20 0.49
▸ TDP2 O95551 1/20 0.49
▸ CASP3 P42574 1/20 0.49
▸ SENP8 Q96LD8 1/20 0.49
▸ SENP7 Q9BQF6 1/20 0.49
▸ SENP6 Q9GZR1 1/20 0.49
▸ TP53 P04637 5/20 0.45
▸ KDM4E B2RXH2 5/20 0.45
▸ TDP1 Q9NUW8 4/20 0.45
▸ HSP90AA1 P07900 4/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ HTT P42858 3/20 0.45
▸ USP2 O75604 1/20 0.45
▸ AXL P30530 1/20 0.40
▸ NSD2 O96028 1/20 0.39
▸ CASP6 P55212 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20278418 0.83 KMT2A (0.45) KMT2AALDH1A1MAPTMEN1APAF1
SCHEMBL3380627 0.77 MEN1 (0.58) KMT2AALDH1A1MAPTMEN1APAF1
SCHEMBL21645154 0.77 KDM4E (0.49) KMT2AALDH1A1MAPTMEN1APAF1
SCHEMBL18980400 0.77 L3MBTL1 (0.50) KMT2AALDH1A1MAPTMEN1APAF1
SCHEMBL11910994 0.76 KDM4E (0.52) KMT2AALDH1A1MAPTMEN1APAF1
SCHEMBL4262317 0.74 MAPT (0.59) KMT2AALDH1A1MAPTMEN1APAF1
SCHEMBL3381245 0.73 KDM4E (0.49) KMT2AALDH1A1MAPTMEN1APAF1
SCHEMBL360202 0.71 — —
SCHEMBL15209183 0.70 KMT2A (0.50) KMT2AALDH1A1MAPTMEN1APAF1
SCHEMBL31266449 0.69 KMT2A (0.53) KMT2AALDH1A1MAPTMEN1APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3558969-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-09-18 — — EP disclosed
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-09-03 — — US disclosed
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. 2022-10-06 — — US disclosed
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-03-23 — — US disclosed
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-03-23 — — US disclosed
EP-3558969-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS Janssen Pharmaceutica NV (BE) 2019-10-30 — — EP disclosed
WO-2018119036-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. (US) 2018-06-28 — — WO disclosed
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN-CILAG (FR) 2018-06-21 — — US disclosed
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN-CILAG (FR) 2018-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 KMT2A 3369/4885ALDH1A1 2543/4885MAPT 2314/4885
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 KMT2A 3369/4885ALDH1A1 2543/4885MAPT 2314/4885
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 KMT2A 3369/4885ALDH1A1 2543/4885MAPT 2314/4885
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 KMT2A 3369/4885ALDH1A1 2543/4885MAPT 2314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback